Cytogenetic Evaluation in 221 Untreated Patients with Myelodysplastic Syndrome

Deviren, Ayhan; Gürsel, İpek Mine; Kuru, Dilhan; Argüden, Yelda Tarkan; Yılmaz, Songül; Çırakoğlu, Ayşe; Hacıhanefioğlu, Seniha

doi:10.5336/medsci.2010-20908

Cited by 3 publications

(6 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…24 In our previous study, we performed a retrospective CC study including 221 untreated MDS patients, and we detected cytogenetic abnormalities in 44.8% patients, which were; -Y (7.7%), -18 (7.7%), -21 (6.8%), -7 (6.3%), -22 (5.4%), -5 (4.5%), +8 (4.5%), -19 (4.5%), del(5q) (1.3%), del (20q) (0.9%), respectively. 25 Our results are coherent with the results of the studies conducted in similar geographical location and population. 24,25 These results support the study of Kawankar et al, suggesting that the frequency of chromosomal aberration may vary according to geographical and ethnic differences.…”

Section: Discussionsupporting

confidence: 91%

“…25 Our results are coherent with the results of the studies conducted in similar geographical location and population. 24,25 These results support the study of Kawankar et al, suggesting that the frequency of chromosomal aberration may vary according to geographical and ethnic differences. 9 As an additional output of our study, we recommend that FISH and CC should be combined in MDS and other genetically heterogeneous diseases.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Miyelodisplastik Sendrom tanısında miR-145 ve miR-146a’nın potansiyel biyobelirteç olarak değerlendirilmesi

Süsgün

Baykara

Yücesan³

et al. 2022

Acta Med Nicomedia

Self Cite

View full text Add to dashboard Cite

Objective: Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic stem cell disorders characterized by ineffective hematopoiesis, bone marrow dysplasia, and peripheral cytopenias. microRNAs (miRNAs) are small non-coding RNAs that play key roles in post-transcriptional regulation of gene expression and have been determined potential in disease diagnostics and therapeutics owing to their stability. Recent evidence suggests that haploinsufficiency of the miR-145 and miR-146a, encoded from 5q Common Deleted Region (CDR) may contribute to the phenotype in MDS. Although, interstitial del(5q) is the most common chromosomal abnormality in MDS, these findings are inconsistent in Turkish patients. Therefore, we aimed to investigate assess the diagnostic value of miR-145/miR-146a and their relation with del(5q) or monosomy 5 in MDS. Methods: In order to determine the association between del(5q) and expression miR-145/miR-146a, conventional cytogenetics (CC), FISH, and qRT-PCR methods were performed for 24 patients with MDS and 20 healthy individuals. Additionally, ROC curves were generated to evaluate putative diagnostic value of miRNAs. Results: Cytogenetic examination revealed clonal cytogenetic abnormalities in 43.4% of cases. miR-146a decreased in 23 of 24 patients regardless of chromosome 5 abnormalities (p

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 91%

Miyelodisplastik Sendrom tanısında miR-145 ve miR-146a’nın potansiyel biyobelirteç olarak değerlendirilmesi

Süsgün

Baykara

Yücesan³

et al. 2022

Acta Med Nicomedia

Self Cite

View full text Add to dashboard Cite

show abstract

“…No significant difference was observed in the average age between Asian MENA and North African MENA populations. We further compared the average age of onset of MENA, Western [28][29][30][31], and Far East populations [32][33][34][35], which were 58.42, 71.15, and 53.92, respectively. Figure 3 displays the interval plot and ANOVA test results for the average age of onset of MDS in the three groups (Western, Far East, and MENA; significantly different, p < 0.0001).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…and MENA populations were not significantly different but both were significantly different to that of the Western population (Figure 3). [28][29][30][31][32][33][34][35]). Letters show significant differences: the same letter b is not significant, whereas a denotes statistically significant differences between groups.…”

Section: Study Characteristicsmentioning

confidence: 99%

Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review

Al-Haidose

Yassin

Ahmed

et al. 2023

JCM

View full text Add to dashboard Cite

Myelodysplastic syndrome (MDS) describes a group of bone marrow malignancies with variable morphologies and heterogeneous clinical features. The aim of this study was to systematically appraise the published clinical, laboratory, and pathologic characteristics and identify distinct clinical features of MDS in the Middle East and North Africa (MENA) region. We conducted a comprehensive search of the PubMed, Web of Science, EMBASE, and Cochrane Library databases from 2000 to 2021 to identify population-based studies of MDS epidemiology in MENA countries. Of 1935 studies, 13 independent studies published between 2000 and 2021 representing 1306 patients with MDS in the MENA region were included. There was a median of 85 (range 20 to 243) patients per study. Seven studies were performed in Asian MENA countries (732 patients, 56%) and six in North African MENA countries (574 patients, 44%). The pooled mean age was 58.4 years (SD 13.14; 12 studies), and the male-to-female ratio was 1.4. The distribution of WHO MDS subtypes was significantly different between MENA, Western, and Far East populations (n = 978 patients, p < 0.001). More patients from MENA countries were at high/very high IPSS risk than in Western and Far East populations (730 patients, p < 0.001). There were 562 patients (62.2%) with normal karyotypes and 341 (37.8%) with abnormal karyotypes. Our findings establish that MDS is prevalent within the MENA region and is more severe than in Western populations. MDS appears to be more severe with an unfavorable prognosis in the Asian MENA population than the North African MENA population.

show abstract

“…18. kromozom kanserle ilişkili çok sayıda geni üzerinde taşıdığı için dikkat çekmektedir. Bunların arasında yer alan önemli genlerden biri de 18q21.3 te lokalize olan BCL2 (B-cell CLL/lymphoma 2) genidir [7][8][9][10][11][12]. MDS'nin çok aşamalı patogenezinin erken evrelerinde proliferasyon avantajlı klon artışları olmaktadır.…”

Section: Olgu Sunumuunclassified

MDS/MPN Tanılı Bir Olguda Klonal Evolüsyon Gösteren Kompleks Karyotip Bulguları

Kuru¹,

Çırakoğlu²,

Yılmaz³

et al. 2019

Pamukkale Medical Journal

Self Cite

View full text Add to dashboard Cite

ÖzetMyelodisplastik/myeloproliferatif neoplaziler (MDS/MPN) displastik ve proliferatif özellikleri bir arada taşıyan klonal myeloid hastalıklardır. MDS/MPN patofizyolojisi myeloid yolakların düzenlenmesindeki bozuklukları kapsamaktadır. En yaygın nedenlerin başında RAS yolağı sinyal proteinlerindeki düzensizlikler gelir. Bu hastalarda BCR/ABL füzyon geni negatiftir.Gerçek zamanlı-polimeraz zincir tepkimesi ile BCR/ABL p210 transkripti (-) ve allele özgü polimeraz zincir tepkimesi yöntemi ile JAK2 V617F mutasyonu (+) saptanan MDS/ MPN ile uyumlu olgunun kemik iliği aspirasyon materyaline 24 ve 48 saatlik standart hücre kültürü uygulanmıştır. GTL bantlama yöntemiyle yapılan sitogenetik inceleme sonucunda, klonal evolüsyon ile meydana gelen idic(18)(p11.2), t(11;idic)( 18))(p11.1;q11) ve dic(11;18)(q24;p11) yeniden düzenlenmelerini de içeren kompleks karyotip tespit edilmiştir. Yaptığımız literatür araştırmasında hematolojik kanserlerde 18 ve 11 numaralı kromozomların katıldığı yeniden düzenlenmeler gözlenirken, bu kromozom düzensizliklerinin kırık noktaları bizim olgumuzdakinden farklı bulunmuştur. Trizomi/ kısmi trizomi 18 lenfoproliferatif hastalıklarda ve MDS'de gözlenen anomalilerden birisi olarak bildirilmektedir. Önemli apoptoz düzenleyici gen ailelerinden biri olan BCL-2, 18. kromozomun uzun kolunda yer almaktadır. Olgumuzda da 18. kromozomun uzun kolunun artışı söz konusudur. Sunduğumuz sitogenetik bulgular kanser genetiği ve alternatif tedavi araştırmalarında hedef bölge olması açısından dikkat çekici olmuştur.

show abstract

Cytogenetic Evaluation in 221 Untreated Patients with Myelodysplastic Syndrome

Cited by 3 publications

References 35 publications

Miyelodisplastik Sendrom tanısında miR-145 ve miR-146a’nın potansiyel biyobelirteç olarak değerlendirilmesi

Miyelodisplastik Sendrom tanısında miR-145 ve miR-146a’nın potansiyel biyobelirteç olarak değerlendirilmesi

Distinct Clinical and Prognostic Features of Myelodysplastic Syndrome in Patients from the Middle East, North Africa, and Beyond: A Systemic Review

MDS/MPN Tanılı Bir Olguda Klonal Evolüsyon Gösteren Kompleks Karyotip Bulguları

Contact Info

Product

Resources

About